Teriparatide 20 mcg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Displaced Atypical Femoral Fractures
Conditions
Non Displaced Atypical Femoral Fractures
Trial Timeline
Jul 1, 2013 → Dec 1, 2022
NCT ID
NCT01896011About Teriparatide 20 mcg
Teriparatide 20 mcg is a phase 3 stage product being developed by Eli Lilly for Non Displaced Atypical Femoral Fractures. The current trial status is completed. This product is registered under clinical trial identifier NCT01896011. Target conditions include Non Displaced Atypical Femoral Fractures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01896011 | Phase 3 | Completed |